144 related articles for article (PubMed ID: 35770260)
1. Effect of cytochrome P450 3A5 polymorphism on the pharmacokinetics of tacrolimus in renal transplant recipients.
Htun YY; Than NN; Swe HK
Korean J Transplant; 2020 Mar; 34(1):24-30. PubMed ID: 35770260
[TBL] [Abstract][Full Text] [Related]
2. CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.
Muller WK; Dandara C; Manning K; Mhandire D; Ensor J; Barday Z; Freercks R
S Afr Med J; 2020 Jan; 110(2):159-166. PubMed ID: 32657689
[TBL] [Abstract][Full Text] [Related]
3. CYP3A5*3 Genetic Polymorphism and Tacrolimus Concentration in Myanmar Renal Transplant Patients.
Htun YY; Swe HK; Saw TM
Transplant Proc; 2018 May; 50(4):1034-1040. PubMed ID: 29731062
[TBL] [Abstract][Full Text] [Related]
4. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients.
Glowacki F; Lionet A; Hammelin JP; Labalette M; Provôt F; Hazzan M; Broly F; Noël C; Cauffiez C
Clin Pharmacokinet; 2011 Jul; 50(7):451-9. PubMed ID: 21528942
[TBL] [Abstract][Full Text] [Related]
5. Effects of CPY3A5 Genetic Polymorphisms on the Pharmacokinetics of Extendedrelease and Immediate-release Tacrolimus Formulations in Renal Transplant Recipients: A Systematic Review and Meta-analysis.
Xie Q; Xiang Q; Liu Z; Mu G; Zhou S; Zhang Z; Ma L; Cui Y
Curr Drug Metab; 2021; 22(10):758-771. PubMed ID: 34525930
[TBL] [Abstract][Full Text] [Related]
6. Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre.
Cheng Y; Li H; Meng Y; Liu H; Yang L; Xu T; Yu J; Zhao N; Liu Y
Int J Clin Pract Suppl; 2015 May; (183):16-22. PubMed ID: 26177012
[TBL] [Abstract][Full Text] [Related]
7. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
Tsuchiya N; Satoh S; Tada H; Li Z; Ohyama C; Sato K; Suzuki T; Habuchi T; Kato T
Transplantation; 2004 Oct; 78(8):1182-7. PubMed ID: 15502717
[TBL] [Abstract][Full Text] [Related]
8. A systematic review of the effect of CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients.
Barry A; Levine M
Ther Drug Monit; 2010 Dec; 32(6):708-14. PubMed ID: 20864901
[TBL] [Abstract][Full Text] [Related]
9. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
[TBL] [Abstract][Full Text] [Related]
10. Effect of
Kim JM; Ryu JH; Lee KW; Hong SK; Yang K; Choi GS; Kim YA; Lee JY; Yi NJ; Kwon CHD; Chu CW; Suh KS; Joh JW
J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32911703
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation.
Benkali K; Rostaing L; Premaud A; Woillard JB; Saint-Marcoux F; Urien S; Kamar N; Marquet P; Rousseau A
Clin Pharmacokinet; 2010 Oct; 49(10):683-92. PubMed ID: 20818834
[TBL] [Abstract][Full Text] [Related]
12. The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
Zhang JJ; Liu SB; Xue L; Ding XL; Zhang H; Miao LY
Int J Clin Pharmacol Ther; 2015 Sep; 53(9):728-36. PubMed ID: 26227094
[TBL] [Abstract][Full Text] [Related]
13. The Cytochrome P450 3A5 Non-Expressor Kidney Allograft as a Risk Factor for Calcineurin Inhibitor Nephrotoxicity.
Udomkarnjananun S; Townamchai N; Chariyavilaskul P; Iampenkhae K; Pongpirul K; Sirichindakul B; Panumatrassamee K; Vanichanan J; Avihingsanon Y; Eiam-Ong S; Praditpornsilpa K
Am J Nephrol; 2018; 47(3):182-190. PubMed ID: 29539600
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic analysis and dosing guidelines for tacrolimus co-administration with Wuzhi capsule in Chinese renal transplant recipients.
Jing Y; Kong Y; Hou X; Liu H; Fu Q; Jiao Z; Peng H; Wei X
J Clin Pharm Ther; 2021 Aug; 46(4):1117-1128. PubMed ID: 33768546
[TBL] [Abstract][Full Text] [Related]
15. Frequencies and Association of CYP3A5 Polymorphism With Tacrolimus Concentration Among Renal Transplant Recipients in Vietnam.
Xuan NT; Hop VQ; Kien TQ; Toan PQ; Thang LV; Binh HT; Van Tran P; Minh HT; Man PT; Cuong HX; Ben NH; Phuong NM; Linh NT; Linh NT; Dung VD; Quyen LTB; Hang DTT; Su HX
Transplant Proc; 2022 Oct; 54(8):2140-2146. PubMed ID: 36085176
[TBL] [Abstract][Full Text] [Related]
16. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients.
Roy JN; Barama A; Poirier C; Vinet B; Roger M
Pharmacogenet Genomics; 2006 Sep; 16(9):659-65. PubMed ID: 16906020
[TBL] [Abstract][Full Text] [Related]
17. Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients.
Uesugi M; Masuda S; Katsura T; Oike F; Takada Y; Inui K
Pharmacogenet Genomics; 2006 Feb; 16(2):119-27. PubMed ID: 16424824
[TBL] [Abstract][Full Text] [Related]
18. Influence of cytochrome P450 3A5 polymorphisms on viral infection incidence in kidney transplant patients treated with tacrolimus.
Hattori Y; Tanaka H; Teranishi J; Ishida H; Makiyama K; Miyajima E; Noguchi K; Kubota Y
Transplant Proc; 2014; 46(2):570-3. PubMed ID: 24656015
[TBL] [Abstract][Full Text] [Related]
19. Effect of drug combination on tacrolimus target dose in renal transplant patients with different
Zhang SF; Tang BH; Wei AH; Du Y; Guan ZW; Li Y
Xenobiotica; 2022 Mar; 52(3):312-321. PubMed ID: 35395919
[TBL] [Abstract][Full Text] [Related]
20. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
